ASIAMEDIC LIMITED
(Incorporated In the Republic of Singapore)
Company Registration No.: 197401556E

DECREASE IN PERCENTAGE SHAREHOLDING IN CRYOVIVA SINGAPORE PTE LTD

The Board of Directors (the "**Board**") of AsiaMedic Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that the Group's shareholding in Cryoviva Singapore Pte Ltd ("**CSPL**") has decreased as a result of the conversion of all shareholders' loans of CSPL into share capital.

The Group's interest in CSPL is held by AsiaMedic CytoLife Pte Ltd ("**CytoLife**"), a wholly-owned subsidiary of the Company. Prior to the conversion, CytoLife and Cryoviva International Pte Ltd ("**CIPL**") held 25% and 75% of the issued share capital respectively in CSPL.

CSPL allotted and issued 377,266 new ordinary shares to CytoLife with the conversion of the shareholder's loan of S$377,266 owing by CSPL to CytoLife. CSPL allotted and issued 2,417,512 new ordinary shares to CIPL with the conversion of the shareholder's loan of S$2,417,512 owing by CSPL to CIPL.

After the aforementioned conversion, CytoLife holds 502,266 ordinary shares, representing 15.24% in CSPL and CSPL is no longer an associated company of the Group.

This transaction is not expected to have a material impact on earnings per share and net tangible assets per share of the Group for the current financial year ending 31 December 2015.

BY ORDER OF THE BOARD

Ms Foo Soon Soo
Company Secretary

18 September 2015

*This announcement has been prepared by the Company and reviewed by the Company's sponsor, Xandar Capital Pte Ltd (the "**Sponsor**"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the correctness of any of the statements made, opinions expressed or reports contained in this announcement.*
Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd)
Address: 3 Shenton Way, #24-02 Shenton House, Singapore 068805
Telephone number: (65) 6319 4954